A5002808124- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Parathyroid Disorders and Treatments
- Hepatitis B Virus Studies
- Dialysis and Renal Disease Management
- Vitamin D Research Studies
- Chronic Lymphocytic Leukemia Research
- Healthcare Policy and Management
- HIV/AIDS drug development and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Potassium and Related Disorders
- Pharmacological Effects and Toxicity Studies
- Primary Care and Health Outcomes
- Liver Disease and Transplantation
- Pancreatitis Pathology and Treatment
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- Chronic Disease Management Strategies
- Healthcare cost, quality, practices
- Electrolyte and hormonal disorders
- Biosimilars and Bioanalytical Methods
- Health, Environment, Cognitive Aging
- Pneumocystis jirovecii pneumonia detection and treatment
- Magnesium in Health and Disease
AbbVie (United States)
2015-2025
Abbott Fund
2008-2012
Abbott (United Kingdom)
2006-2012
Abbott (United States)
2007-2011
Abbott (Germany)
2007
BackgroundOptimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titrated paricalcitol plus supplemental cinacalcet only hypercalcaemia is superior to low-dose vitamin D in controlling intact parathyroid hormone (iPTH) levels patients with on haemodialysis.
Background. Abnormalities of serum calcium, phosphorous and intact parathyroid hormone (PTH) are associated with morbidity mortality in haemodialysis patients. Pharmacologic parenteral vitamin D administration is used to correct these abnormalities; however, the relationship between therapies hospitalizations has never been addressed.
Hepatitis G virus (HGV) and its strain variant, the GB agent (GBV-C) are independent isolates of a recently identified non-A through -E hepatitis virus. Prevalence in United States volunteer blood donors is 1.5 to 1.9 percent, but no data on European available. Epidemiologic suggest preferred parenteral transmission route. The prevalence HGV/GBV-C efficiency transfusion recipients were investigated.Plasma samples from unpaid German tested for by in-house reverse transcription-polymerase...
<i>Background/Aims:</i> The objective of this study was to examine health care costs and utilization the risks dialysis or mortality among diabetic predialysis chronic kidney disease (CKD) patients with without secondary hyperparathyroidism (SHPT). <i>Methods:</i> This retrospective, matched cohort examined insurance claims from 703 adult CKD SHPT during a 72-month follow-up period. Annualized estimates service utilization, progression death following index diagnosis...
Although hepatitis C virus (HCV) infection remains a major clinical, economic, and societal burden, the development of curative antiviral therapy may accelerate path toward elimination. This analysis assessed progress United States (US) states towards achieving World Health Organization's (WHO) 2030 HCV elimination targets for incidence, mortality, diagnosis, treatment. A previously published Markov model was used to simulate progression over time estimate in each state based on prevalence,...
Objective:This descriptive study assessed the rate and costs of surgical procedures among newly diagnosed endometriosis patients.Methods:Utilizing Medstat MarketScan database, commercially insured women aged 18–45 with during 2006–2007 were identified. Each patient was matched to four without (population controls) based on age region residence. Surgical received 12 months post-diagnosis assessed. Costs amount paid by insurance companies.Results:This identified 15,891 63,564 population...
Clinical trials have demonstrated the efficacy of all-oral direct-acting antiviral (DAA) regimens in treatment patients infected with hepatitis C virus (HCV). This study assessed real-world effectiveness two recently approved regimens; paritaprevir/ritonavir/ombitasvir; dasabuvir (3D), and sofosbuvir/ledipasvir (SOF/LDV) HCV genotype 1. A retrospective analysis administrative claims data (IMS Health Patient-Centric Data Warehouse/Medivo database) from October 1, 2013 to August 14, 2015 was...
Glecaprevir/pibrentasvir (G/P) was approved on 26 September 2019 by the US Food and Drug Administration for 8-week duration in treatment-naïve (TN) hepatitis C virus (HCV)-infected patients with compensated cirrhosis (CC). Evidence from EXPEDITION-8 study demonstrated that 8 weeks of G/P achieved a 98% intent-to-treat (ITT) sustained virologic response rate 12 post treatment (SVR12) 343 TN/CC patients. The aim this is to demonstrate first real-world effectiveness genotype 1–6 HCV Data 73 who...
The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment an 8-week glecaprevir/pibrentasvir (G/P) regimen. Further real-world evidence is needed to support the effectiveness G/P in practice setting and consolidate these treatment recommendations. aim this study contribute for TN/CC 1–6. Retrospective data from 494 were...
Background and objectives: Secondary hyperparathyroidism (SHPT) can lead to significant morbidity, mortality, additional healthcare resource utilization in chronic kidney disease (CKD) stage 5. The objective of this study was examine costs utilization, the risks dialysis or among pre-dialysis CKD patients with without SHPT.Research design methods: This retrospective cohort examined insurance claims from 66 644 adult, pre-dialysis, SHPT during a 72-month period. Annualized estimates...
Background. Paricalcitol and cinacalcet are common therapies for patients on haemodialysis with secondary hyperparathyroidism (SHPT). We conducted a multi-centre study in 12 countries to compare the safety efficacy of paricalcitol treatment SHPT.
Chronic infection with hepatitis C virus (HCV) is a leading cause of liver disease and infectious deaths. While recent emerging treatment options for HCV patients have enabled higher rates sustained virologic response (SVR), the demographic, clinical, geographic, payer characteristics estimated 3.4 million chronic in USA are poorly understood. The goal this study was to create dataset describing current patient landscape USA. Data from two large national laboratory companies representing...
Objective: This study compared the cost-effectiveness of direct-acting antiviral therapies currently recommended for treating genotypes (GT) 1 and 4 chronic hepatitis C (CHC) patients in US.Methods: A analysis treatments CHC from a US payer's perspective over lifelong time horizon was performed. Markov model based on natural history used population that included treatment-naïve -experienced patients. Treatment alternatives considered GT1 ombitasvir/paritaprevir/ritonavir + dasabuvir ±...
The objective of this study was to determine the cost effectiveness paricalcitol versus calcitriol for treatment secondary hyperparathyroidism in patients with chronic kidney disease United States setting.A Markov process model developed employing data sources from published literature, clinical trials and observational studies, official US price/tariff lists national population statistics. comparator calcitriol, a non-selective vitamin D receptor activator (VDRA) medication. primary...
Objectives:Persistence and compliance in women with endometriosis who are receiving gonadotropin-releasing hormone agonists (GnRH-a) may be limited by its hypoestrogenic side effects. Use of concomitant therapy norethindrone acetate (NA), estrogen, estrogen/progestin combinations, or other progestin (i.e., 'add-back therapy' [ABT]) is recommended to alleviate these This retrospective study evaluated ABT utilization effect on persistence patients taking the GnRH-a leuprolide (LA) depot...
Direct-acting antiviral (DAA) therapy is highly effective in curing hepatitis C virus (HCV) infection people who inject drugs (PWID). Previous studies showed declining persistence to DAA over the course of treatment. This study compares real-world medication prescription refills for 8- versus 12-week treatment-naïve PWID with chronic HCV compensated cirrhosis or without cirrhosis. Symphony Health's claims database was used collect data from patients aged ≥ 12 years were prescribed between...
Hepatitis C virus (HCV) is the most common bloodborne chronic infection in US. Following approval of highly effective, direct-acting antivirals 2014, diagnostic and treatment rates for HCV US have evolved. This study assessed number individuals with screening or testing clinical characteristics HCV-infected between 2017 2019. Individuals screened antibody and/or tested ribonucleic acid (RNA) from to 2019 by two large laboratory companies were included this analysis. Clinical characteristics,...
Objective:To estimate the impact of elevated intact parathyroid hormone levels on time to death and renal replacement therapy in patients with chronic kidney disease stages 3 4.Methods:A retrospective cohort analysis from 01/1996 09/2007 was conducted 11,092 4 using Cockroft–Gault Modification Diet Renal Disease equations their glomerular filtration rates. Patients' highest were used define index date (followed for 1 year). Mortality events evaluated among cohorts at pre-defined...